PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.16%
R&D growth while TRAW reduces spending. John Neff would investigate strategic advantage.
23.98%
G&A change of 23.98% while TRAW maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
7.46%
Other expenses change of 7.46% while TRAW maintains costs. Bruce Berkowitz would investigate efficiency.
15.26%
Operating expenses growth while TRAW reduces costs. John Neff would investigate differences.
15.26%
Total costs growth while TRAW reduces costs. John Neff would investigate differences.
-36.68%
Interest expense reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine advantage.
7.46%
D&A change of 7.46% while TRAW maintains D&A. Bruce Berkowitz would investigate efficiency.
-50.67%
EBITDA decline while TRAW shows 28.30% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-15.26%
Operating income decline while TRAW shows 28.20% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-81.62%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-50.43%
Pre-tax income decline while TRAW shows 25.68% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-36.68%
Tax expense reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine advantage.
-50.43%
Net income decline while TRAW shows 25.68% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-43.14%
EPS decline while TRAW shows 25.91% growth. Joel Greenblatt would examine position.
-43.14%
Diluted EPS decline while TRAW shows 25.91% growth. Joel Greenblatt would examine position.
5.01%
Share count reduction below 50% of TRAW's 0.31%. Michael Burry would check for concerns.
5.01%
Diluted share reduction below 50% of TRAW's 0.31%. Michael Burry would check for concerns.